Sign in

    Steve Jensen

    Research Analyst at Jensen Capital Management

    Steve Jensen is a Research Analyst at Jensen Capital Management, focused primarily on the healthcare sector with coverage that includes Provectus Biopharmaceuticals. While his performance record is limited in public sources, he has participated in earnings calls and engaged with company management as part of his analytical work. Details on his career trajectory, prior roles, credentials, or broader coverage universe are not available in currently accessible databases, and no TipRanks or industry recognition metrics could be verified. Public records do not confirm any securities licenses or FINRA registrations under his name.

    Steve Jensen's questions to PROVECTUS BIOPHARMACEUTICALS (PVCT) leadership

    Steve Jensen's questions to PROVECTUS BIOPHARMACEUTICALS (PVCT) leadership • Q2 2016

    Question

    Steve Jensen of Jensen Capital Management inquired about management's personal sentiment on the company's current status and also asked for details on the company's cash position and future financing plans.

    Answer

    Interim CEO, COO & CFO Peter Culpepper expressed strong personal conviction in the company's mission and the potential of its drug candidates, emphasizing a focus on perseverance to achieve success. CTO Eric Wachter added that from a technology standpoint, the company is in its strongest position ever. Regarding financing, Culpepper acknowledged the need to raise capital in the current quarter to continue operations until a non-dilutive partnership could be secured, stating confidence in obtaining funds from dedicated stockholders while minimizing dilution.

    Ask Fintool Equity Research AI